Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01436357 · ClinicalTrials.gov registry record · Phase 1
Staged Phase I/II Hepatitis C Prophylactic Vaccine
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 548
- Enrollment target
NCT01436357 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 548 participants.
The verdict
NCT01436357, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 548 participants
- Enrollment target
Study Summary
A two stage, phase I/II, double-blinded, randomized, placebo-controlled study of hepatitis C virus (HCV)uninfected male and female injection drug users (IDU) aged 18 to 45. AdCh3NSmut1 and MVA-NSMut HCV vaccine will be administered to 68 (+/-4) volunteers in stage 1. A planned interim analysis of safety and immunogenicity will be conducted. If no safety signal is detected and there is evidence of a measurable immune response to HCV then 472 (+/-4) volunteers will be enrolled in stage 2. Primary objectives are to 1) assess the safety of AdCh3NSmut1 and MVA-NSmut compared to placebo when administered to HCV-uninfected IDUs and 2) determine if AdCh3NSmut1 and MVA-NSmut HCV vaccines will reduce incidence of chronic HCV infection compared to placebo among HCV-uninfected IDUs. Planned study duration is approx 63 months (accrual time, 2 months vaccination, 18 months follow-up, and 9 months extended observation for subjects becoming viremic in the last month of follow-up).
Interventions
- OTHER Placebo
- BIOLOGICAL AdCh3NSmut1
- BIOLOGICAL MVA-NSmut
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 548 participants |
| Start Date | 2012-03-06 |
| Est. Completion | 2018-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01436357
The ClinicalTrials.gov registry entry for NCT01436357 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 548 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01436357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01436357 about?
NCT01436357 is a clinical study titled "Staged Phase I/II Hepatitis C Prophylactic Vaccine". A two stage, phase I/II, double-blinded, randomized, placebo-controlled study of hepatitis C virus (HCV)uninfected male and female injection drug users (IDU) aged 18 to 45. AdCh3NSmut1 and MVA-NSMut HCV vaccine will be administered to 68 (+/-4) volunteers in stage 1. A planned interim analysis of sa...
What is the current status of trial NCT01436357?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 548 participants. The study started on 2012-03-06. Estimated completion is 2018-05-25.
What interventions are being tested in trial NCT01436357?
The interventions under investigation include: Placebo (OTHER), AdCh3NSmut1 (BIOLOGICAL), MVA-NSmut (BIOLOGICAL).
Who is sponsoring clinical trial NCT01436357?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.